Assessment of Bronchial Obstruction in Adolescents With HIV

HIV Clinical Trial

— ResppedHIV  

Official title:

Assessment of Bronchial Obstruction in Adolescents With HIV

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05869084
• Other study ID #: APHP211566
• Secondary ID: IDRCB: 2021-A026
• Status: Completed
• Phase: N/A
• Start date: March 1, 2022
• Est. completion date: July 1, 2022

Study information

• Verified date: May 2023
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In children, data from the literature find a higher prevalence of asthma in the population treated for HIV. Bronchial hyperreactivity, indicative of chronic inflammation and bronchial obstruction, is also present. Screening for early peripheral obstruction could therefore make it possible to initiate appropriate anti-inflammatory treatment, if necessary, and early preventive management.

Description:

In adults chronically infected with HIV, there is an increased prevalence impaired respiratory function, with a greater occurrence of COPD than in the uninfected population. In children, data from the literature find a prevalence of greater atopy in the HIV-infected pediatric population. Furthermore, a bronchial hyperreactivity or even peripheral bronchial obstruction, indicative of a local chronic inflammation has been found in young adolescents treated since the birth for HIV infection in utero. Screening for early peripheral obstruction in HIV-infected adolescents could therefore make it possible to initiate, if necessary, a anti-inflammatory treatment, and early management to prevent the occurrence of impaired respiratory function in adulthood For this this single-center prospective study chose to perform respiratory function explorations with forced oscillometry with the Endpoint main factor of the peripheral obstruction the R5HZ parameter expressed in % predicted. Patients from 11 to 25 years to whom it was proposed added to that to answer a questionnaire of respiratory quality of life

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: July 1, 2022
• Est. primary completion date: June 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 11 Years to 25 Years

Eligibility

Inclusion Criteria:

• Children over 11 and Under 25-year-old infected with HIV and on antiretrovirals and followed up at Robert Debré hospital for this pathology
• Consent of the holders of parental authority and Patients informed and not objecting to participate in research Exclusion Criteria : •
• Age = 11 years old
• Not treated for HIV
• Patients under guardianship / curatorship

Related Conditions & MeSH terms

• HIV

Intervention

Diagnostic Test:
• pulmonary function tests
pulmonary function tests

Locations

Country	Name	City	State
France	Robert Debre Hospital	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Resistance measured by forced oscillometry (5hZ)	Resistance measured by forced oscillometry (5hZ)	24 hours